U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06847139) titled 'Effect of Zinc Supplementation on Hyperhomocysteinemia Compared to Follic Acid in CKD Patient on Hemodialysis' on Feb. 21.
Brief Summary: Hyperhomocysteinemia is a well-recognized risk factor for accelerated cardiovascular events in hemodialysis patients. Hyperhomocysteinemia is common in individuals with chronic kidney disease (CKD). Zinc is a vital cofactor for homocysteine metabolism enzymes. Although numerous studies have demonstrated the efficacy of folic acid in hyperhomocysteinemia, zinc supplementation has the potential to reduce homocysteine levels in hemodialysis patients. Objective: To evaluate the effect of Zinc suppleme...